KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Gains from Investment Securities (2017 - 2025)

Historic Gains from Investment Securities for Bionano Genomics (BNGO) over the last 7 years, with Q2 2025 value amounting to $3.0 million.

  • Bionano Genomics' Gains from Investment Securities rose 16668.9% to $3.0 million in Q2 2025 from the same period last year, while for Sep 2025 it was $3.0 million, marking a year-over-year increase of 12813.63%. This contributed to the annual value of -$10.9 million for FY2024, which is 64555.4% down from last year.
  • Per Bionano Genomics' latest filing, its Gains from Investment Securities stood at $3.0 million for Q2 2025, which was up 16668.9% from -$19000.0 recorded in Q1 2025.
  • In the past 5 years, Bionano Genomics' Gains from Investment Securities registered a high of $3.0 million during Q2 2025, and its lowest value of -$4.5 million during Q2 2024.
  • Moreover, its 5-year median value for Gains from Investment Securities was $296000.0 (2021), whereas its average is $16400.0.
  • In the last 5 years, Bionano Genomics' Gains from Investment Securities surged by 3562500.0% in 2023 and then crashed by 55161.29% in 2024.
  • Over the past 5 years, Bionano Genomics' Gains from Investment Securities (Quarter) stood at $2.4 million in 2021, then plummeted by 99.84% to $4000.0 in 2022, then plummeted by 99850.0% to -$4.0 million in 2023, then surged by 99.75% to -$10000.0 in 2024, then skyrocketed by 29950.0% to $3.0 million in 2025.
  • Its last three reported values are $3.0 million in Q2 2025, -$19000.0 for Q1 2025, and -$10000.0 during Q4 2024.